Single genome-editing strategy can help treat multiple disorders

Now I have enough grounded facts to write the note.

1. At a Glance

• A prime editing-based genome-editing strategy called PERT (Prime Editing-mediated Readthrough of premature Termination codons) can potentially treat many different genetic diseases caused by nonsense mutations using one platform instead of a bespoke therapy per disease [S1][S4].
• Relevant for UPSC as a Science & Tech current-affairs item bridging biotechnology, genetic disorders, and disease-agnostic drug development — a recurring GS-III theme (biotechnology applications in health).
• Developed by researchers at the Broad Institute (MIT & Harvard), Harvard University, and the University of Minnesota; led by David Liu, a pioneer of base editing and prime editing [S1][S4].
• Published in the journal Nature (Vol. 648, 4 December 2025) [S4].

2. Why in the News

• The study "Prime editing-installed suppressor tRNAs for disease-agnostic genome editing" was published in Nature and reported by the Broad Institute in November 2025, with coverage picked up by international science media and reproduced in Indian print media (The Hindu, 17 February 2026 edition) [S1][S4][Article excerpt].

3. Background & Evolution

• Nonsense mutations are a class of DNA point mutations that insert a premature stop codon (UAA/UAG/UGA) into an mRNA, truncating protein synthesis before a complete, functional protein is made [Article excerpt][S6].
• They are known to underlie a wide range of monogenic disorders, including cystic fibrosis (CFTR gene, e.g., mutation W1282X), Batten disease, Tay-Sachs disease, Niemann-Pick disease type C1, Duchenne muscular dystrophy, beta-thalassemia, Hurler syndrome, and certain cancers [S6][Article excerpt].
• Historically, each nonsense-mutation disease required its own therapy (e.g., readthrough drugs like Ataluren for specific CFTR/DMD mutations), each needing separate design, testing, and regulatory approval — a slow, costly, disease-by-disease model [S6][Article excerpt].
• Prime editing itself (precise, template-guided DNA editing without double-strand breaks) was developed earlier by David Liu's lab as a refinement beyond CRISPR-Cas9 base editing; PERT builds on this platform [S1].

4. Core Static Facts

5. Multi-Dimensional Analysis

• Scientific/Technological: Represents a shift from "one mutation, one therapy" to a disease-agnostic platform approach in gene therapy — a single editing tool with a modular sup-tRNA payload adaptable across indications [S1].
• Economic: Could sharply cut the cost and time of orphan/rare-disease drug development, since currently each nonsense-mutation disease needs independent trials and regulatory review [Article excerpt].
• Health/Social: Chiefly benefits patients with rare genetic disorders (many pediatric, often fatal, e.g., Batten disease, Tay-Sachs) for whom individualized drug development is commercially unviable ("orphan drug" problem) [S1].
• Ethical/Governance: Raises standard genome-editing governance questions — germline vs somatic application, long-term safety of tRNA modification, regulatory pathway for "platform" therapies rather than single-indication drugs (relevant to India's biosafety/biotech regulatory framework debates).
• Administrative: Still at preclinical (cell model) stage — no human trials yet; translation to clinical use will need extended safety/efficacy testing and regulatory frameworks equipped for platform-based rather than disease-specific approvals [S1].

6. Recent Developments (last 12-18 months)

• November 2025: Broad Institute publicizes the PERT study ahead of/alongside journal publication [S1].
• 4 December 2025: Study "Prime editing-installed suppressor tRNAs for disease-agnostic genome editing" published in Nature, Vol. 648, p.191 [S4].
• 17 February 2026: The Hindu (International page, Print Edition p.7) carries a science explainer on the study titled "Single genome-editing strategy can help treat multiple disorders" [Article excerpt].

7. Prelims Hooks

• Nonsense mutations account for roughly a quarter (per source article) of all known disease-causing genetic changes [Article excerpt].
• A nonsense mutation inserts a premature stop codon into DNA/mRNA, halting protein synthesis early [Article excerpt].
• The new genome-editing strategy is named PERT (Prime Editing-mediated Readthrough of premature Termination codons) [S1].
• PERT uses prime editing, not CRISPR-Cas9 base editing, as its core tool [S1].
• PERT works by converting a dispensable endogenous tRNA into a suppressor tRNA (sup-tRNA) [S1].
• The study screened variants across all 418 human tRNAs [S1].
• PERT was tested in cell models of Batten disease, Tay-Sachs disease, and Niemann-Pick disease type C1 [S1].
• The study was published in the journal Nature, Volume 648, dated 4 December 2025 [S4].
• Lead research institutions: Broad Institute, Harvard University, University of Minnesota [S1].
• The concept lead scientist, David Liu, also pioneered base editing and prime editing technologies [S1].
• Cystic fibrosis is a classic example disease caused by nonsense mutations in the CFTR gene [S6][Article excerpt].
• Batten disease is a rare, fatal neurodegenerative genetic disorder used as a test case for PERT [S1][Article excerpt].
• An existing (older) disease-specific readthrough drug for nonsense-mutation diseases is Ataluren [S6].
• The traditional model for treating nonsense-mutation diseases required a separate therapy per mutation, which is slow and expensive [Article excerpt].
• PERT aims to be disease-agnostic, i.e., theoretically applicable across multiple unrelated nonsense-mutation disorders with one platform [S1].

8. Mains Relevance

• GS-III: Science and Technology — developments in biotechnology; genetic engineering; applications in everyday life; issues relating to Intellectual Property Rights (relevant if PERT is commercialized).
• GS-II (secondary angle): Health governance — regulatory frameworks for gene therapies, orphan/rare-disease policy, bioethics.
• Possible Mains question stems: 1. "Discuss how gene-editing technologies such as prime editing are transforming the treatment paradigm for rare genetic disorders. What regulatory and ethical challenges does India face in adopting such platform therapies?" (GS-III) 2. "What are nonsense mutations, and why has a 'disease-agnostic' approach to their correction been considered a breakthrough in genetic medicine?" (GS-III) 3. "Examine the economic and ethical implications of platform-based gene therapies for rare/orphan diseases in developing countries like India." (GS-II/III)

9. Related Topics to Study Next

• CRISPR-Cas9 gene editing — foundational technology preceding prime editing; frequently tested in Prelims.
• Base editing vs Prime editing — key technical distinction relevant to biotech questions.
• Rare/Orphan diseases policy in India — National Policy for Rare Diseases, 2021 (MoHFW) — governance angle.
• Gene therapy regulation in India — Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT) guidelines on gene therapy products.
• Cystic fibrosis, Duchenne Muscular Dystrophy, Tay-Sachs, Batten disease — examples of monogenic disorders frequently referenced in bio-based Prelims questions.
• Human Genome Editing ethical debates — germline vs somatic editing, WHO's global governance framework on human genome editing.
• DBT/BIRAC biotechnology promotion schemes — India's institutional biotech ecosystem, relevant to "Make in India" biotech push.
• CAR-T cell therapy in India — another recent gene/cell-based therapeutic breakthrough (NexCAR19), useful comparative case.

10. Common Errors / Trap Areas

• Do not confuse nonsense mutation (premature stop codon) with missense mutation (amino acid substitution) or frameshift mutation (insertion/deletion altering reading frame) — commonly conflated in MCQs.
• Do not confuse prime editing with base editing or CRISPR-Cas9 — each is a distinct, related but technically different genome-editing tool.
• The lead institution is the Broad Institute (MIT & Harvard), not MIT or Harvard alone — often misattributed.
• PERT is currently only tested in human cell models, not in clinical/human trials — avoid stating it as an approved therapy.
• The exact percentage of genetic diseases attributable to nonsense mutations varies by source (article says ~a quarter; some scientific literature cites ~11-20% of point mutations, others up to ~30% of rare diseases) — cite cautiously and avoid treating one figure as universally fixed.

11. Sources

• [S1] Single prime editing system could potentially treat multiple genetic diseases — Broad Institute — https://www.broadinstitute.org/news/single-prime-editing-system-could-potentially-treat-multiple-genetic-diseases — (tier: 4)
• [S4] Prime editing-installed suppressor tRNAs for disease-agnostic genome editing — Nature — https://www.nature.com/articles/s41586-025-09732-2 — (tier: 3)
• [S6] Therapeutic Nonsense Suppression Modalities: From Small Molecules to Nucleic Acid-Based Approaches — NCBI/PMC — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11201248/ — (tier: 3)
• [Article excerpt] "Single genome-editing strategy can help treat multiple disorders," The Hindu (International), 17 February 2026, Print Edition p.7 — https://www.thehindu.com/todays-paper/2026-02-17/th_international/articleG1AFJKUFS-13546759.ece — (tier: 4)